Skip to content

The effects of uromic toxins on Hemodialysis patients immune function

The effects of uromic toxins on Hemodialysis patients immune function

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TTRCC-14004967
Enrollment
Unknown
Registered
2014-06-05
Start date
2014-07-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis patients

Interventions

High-throughput dialyzer group:Using high-flux polysulfone membrane
hemodialysis and hemodiafiltration group:Hemodiafiltration therapy
Hemodialysis and hemoperfusion therapy group:Hemoperfusion

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years; (2) Hemodialysis three times per week; (3) Hemodialysis time longer than 3 months; (4) Signed informed consent.

Exclusion criteria

Exclusion criteria: (1) HIV-positive; (2) fever and other signs of infection, active ulcers within a month; (3) cerebral ischemia, myocardial infarction and other cardiovascular and cerebrovascular events within a mouth; (4) blood diseases or malignancy, cachexia; (5) pregnant or not effective contraceptive measures women of childbearing age; (6) combined immune system diseases; (7) the application jugular vein catheter (temporary and long-term).

Design outcomes

Primary

MeasureTime frame
Creatinine;Urea nitrogen;beta 2 microglobulin;iPTH;Advanced oxidation protein products;High-sensitivity C-reactive protein;Interleukin-1;Interleukin-6;Interleukin-10;TGF-beta;Peripheral mononuclear cells;Regulate B lymphocytes;Immunoglobulins and complement;

Countries

China

Contacts

Public ContactHongli Lin
linhongli@vip.163.com+86 18098875667

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026